Claims for Patent: 10,080,734

Summary for Patent: 10,080,734

Title:	Method for treating autism and other neurodevelopmental disorders
Abstract:	A method for treating autism and other neurodevelopmental disorders including the step of administering an effective amount of an isothiocyanate functional surfactant to a human, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. The administration of the isothiocyanate functional surfactant may be augmented with a NMDA-receptor antagonist and/or a TNF-.alpha. inhibiting agent.
Inventor(s):	Silver; Michael E. (Lake City, MI)
Assignee:	The William M. Yarbrough foundation (Peoria, IL)
Application Number:	15/792,097
Patent Claims:	1. A method for treating autism or other neurodevelopmental disorders, comprising the step(s) of: administering to a patient in need thereof an effective amount of an isothiocyanate functional surfactant, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. 2. The method for treating autism or other neurodevelopmental disorders according to claim 1, further comprising the step of administering a NMDA-receptor antagonist to the patient. 3. The method for treating autism or other neurodevelopmental disorders according to claim 2, wherein the NMDA-receptor antagonist comprises 1-amino-3,5-dimethyladamantane or a pharmaceutically acceptable salts thereof. 4. The method for treating autism or other neurodevelopmental disorders according to claim 2, further comprising the step of administering a TNF-.alpha. inhibiting agent to the patient. 5. The method for treating autism or other neurodevelopmental disorders according to claim 4, wherein the TNF-.alpha. inhibiting agent is selected from at least one of Lenalinomide, Thalidomide, L-Camosine, Infliximab, Etanercept, a stem cell preparation, isomers thereof, or pharmaceutically acceptable salts thereof. 6. The method for treating autism or other neurodevelopmental disorders according to claim 1, further comprising the step of administering a TNF-.alpha. inhibiting agent to the patient. 7. The method for treating autism or other neurodevelopmental disorders according to claim 6, wherein the TNF-.alpha. inhibiting agent is selected from at least one of Lenalinomide, Thalidomide, L-Camosine, Infliximab, Etanercept, a stem cell preparation, isomers thereof, or pharmaceutically acceptable salts thereof. 8. A method for treating autism or other neurodevelopmental disorders, comprising the step(s) of: administering to a patient in need thereof an effective amount of a lysine derivative, wherein the lysine derivative comprises an .alpha.-nitrogen and a .epsilon.-nitrogen, and wherein an alkyl and/or alkanoyl substituent comprising at least approximately 8 carbon atoms is associated with the .alpha.-nitrogen, and further wherein at least one isothiocyanate functional group is associated with the .epsilon.-nitrogen. 9. The method for treating autism or other neurodevelopmental disorders according to claim 8, further comprising the step of administering a NMDA-receptor antagonist to the patient. 10. The method for treating autism or other neurodevelopmental disorders according to claim 8, further comprising the step of administering a TNF-.alpha. inhibiting agent to the patient. 11. A method for treating autism or other neurodevelopmental disorders, comprising the step(s) of: administering to a patient in need thereof an effective amount of a surfactant or a pharmaceutically acceptable salt thereof, wherein the protonated form of the surfactant is represented by the following chemical structure: ##STR00015## wherein R.sub.1 comprises an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 1 to approximately 25 carbon atom(s), wherein the carbon atom(s) may be a linking group to, or part of, a halogen, a N, O, and/or S containing moiety, and/or one or more functional groups comprising alcohols, esters, ammonium salts, phosphonium salts, and combinations thereof; a linkage to a dimer; a linkage to an oligomer; and/or a linkage to a polymer; wherein R.sub.2 comprises NCS; and wherein R.sub.3-R.sub.5 are the same or different and comprise H; OH; an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 1 to approximately 25 carbon atom(s), wherein the carbon atom(s) may be a linking group to, or part of, a halogen, a N, O, and/or S containing moiety, and/or one or more functional groups comprising alcohols, esters, ammonium salts, phosphonium salts, and combinations thereof; a linkage to a dimer; a linkage to an oligomer; and/or a linkage to a polymer with the proviso that at least one of R.sub.3-R.sub.5 comprise an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 8 to approximately 25 carbon atom(s). 12. The method for treating autism or other neurodevelopmental disorders, according to claim 11, wherein the protonated form of the surfactant is represented by the following chemical structure: ##STR00016## wherein X comprises an integer ranging from approximately 1 to approximately 25, and wherein Y comprises an integer ranging from approximately 6 to approximately 25. 13. The method for treating autism or other neurodevelopmental disorders, according to claim 11, wherein the protonated form of the surfactant is represented by the following chemical structure: ##STR00017## 14. The method for treating autism or other neurodevelopmental disorders according to claim 13, further comprising the step of administering a NMDA-receptor antagonist to the patient. 15. The method for treating autism or other neurodevelopmental disorders according to claim 14, wherein the NMDA-receptor antagonist comprises 1-amino-3,5-dimethyladamantane or a pharmaceutically acceptable salts thereof. 16. The method for treating autism or other neurodevelopmental disorders according to claim 11, further comprising the step of administering a TNF-.alpha. inhibiting agent to the patient. 17. The method for treating autism or other neurodevelopmental disorders according to claim 16, wherein the TNF-.alpha. inhibiting agent is selected from at least one of Lenalinomide, Thalidomide, L-Camosine, Infliximab, Etanercept, a stem cell preparation, isomers thereof, or pharmaceutically acceptable salts thereof. 18. The method for treating autism or other neurodevelopmental disorders, according to claim 11, wherein the deprotonated form of the surfactant is represented by the following chemical structure: ##STR00018## wherein R.sub.1 comprises an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 1 to approximately 25 carbon atom(s), wherein the carbon atom(s) may be a linking group to, or part of, a halogen, a N, O, and/or S containing moiety, and/or one or more functional groups comprising alcohols, esters, ammonium salts, phosphonium salts, and combinations thereof; a linkage to a dimer; a linkage to an oligomer; and/or a linkage to a polymer; wherein R.sub.2 comprises NCS; wherein R.sub.3-R.sub.5 are the same or different and comprise H; OH; an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 1 to approximately 25 carbon atom(s), wherein the carbon atom(s) may be a linking group to, or part of, a halogen, a N, O, and/or S containing moiety, and/or one or more functional groups comprising alcohols, esters, ammonium salts, phosphonium salts, and combinations thereof; a linkage to a dimer; a linkage to an oligomer; and/or a linkage to a polymer with the proviso that at least one of R.sub.3-R.sub.5 comprise an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 8 to approximately 25 carbon atom(s), wherein X comprises a counter cation such as, but not limited to, alkali metals, alkaline earth metals, transition metals, s-block metals, d-block metals, p-block metals, NZ.sub.4.sup.+, wherein Z comprises, H, R.sub.6, and/or OR.sub.6, and wherein R.sub.6 comprises an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 1 to approximately 25 carbon atom(s), wherein the carbon atom(s) may be a linking group to, or part of, a halogen, a N, O, and/or S containing moiety, and/or one or more functional groups comprising alcohols, esters, ammonium salts, phosphonium salts, and combinations thereof; a linkage to a dimer; a linkage to an oligomer; and/or a linkage to a polymer. 19. The method for treating autism or other neurodevelopmental disorders, according to claim 11, further comprising the step of administering an additional surfactant, wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, and combinations thereof. 20. The method for treating autism or other neurodevelopmental disorders, according to claim 11, wherein R.sub.1 is selected from the group consisting of an alkyl, aryl, alkoxy, alkanoyl, aroyl, alkenyl, and cyano group containing 1 to approximately 25 carbon atom(s); wherein R2 is NCS; and wherein R3-R5 are each independently selected from the group consisting of H, OH, and an alkyl, aryl, alkoxy, alkanoyl, aroyl, alkenyl, and cyano group containing 1 to approximately 25 carbon atom(s) with the proviso that at least one of R3-R5 is selected from the group consisting of an alkyl, aryl, alkoxy, alkanoyl, aroyl, alkenyl, and cyano group containing approximately 8 to approximately 25 carbon atom(s). 21. The method for treating autism or other neurodevelopmental disorders, according to claim 18, wherein R.sub.1 is selected from the group consisting of an alkyl, aryl, alkoxy, alkanoyl, aroyl, alkenyl, and cyano group containing 1 to approximately 25 carbon atom(s); wherein R2 is NCS; and wherein R3-R5 are each independently selected from the group consisting of H, OH, and an alkyl, aryl, alkoxy, alkanoyl, aroyl, alkenyl, and cyano group containing 1 to approximately 25 carbon atom(s) with the proviso that at least one of R3-R5 is selected from the group consisting of an alkyl, aryl, alkoxy, alkanoyl, aroyl, alkenyl, and cyano group containing approximately 8 to approximately 25 carbon atom(s), and wherein X is a counter cation.

Details for Patent 10,080,734

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2032-07-26
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2032-07-26
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2032-07-26